Published in Biotech Law Weekly, August 26th, 2005
"A conventional dendritic cell (DC)-based immunotherapy has been tested clinically for treatment of patients with advanced cancer but requires modification to further improve the clinical results. In this study, we evaluated the in vivo antitumor effects of DC therapy, non-viral-mediated interleukin (IL)-12 gene therapy, and a combination of the two in a murine bilateral subcutaneous tumor model," scientists in Japan report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.